Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 1, 2008, Pages 43-65

  Camins, A ^a   Pallàs, Mercè ^a   Silvestre, J S ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Prous Science ^*  (Spain)

Author keywords

Antioxidants; Apoptosis; COX 2; Cyclin dependent kinases; Glutamate receptors; Neuronal cell death; p53

Indexed keywords

ALPHA TOCOPHEROL; AM 36; ANTIOXIDANT; APOPTOSIS INDUCING FACTOR; AR A014418; BN 82451; CARBAZOMADURIN A; CARBAZOMADURIN B; CELL CYCLE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C; EBSELEN; EN 289327; EN 302041; EN 302049; EN 302050; EN 302051; EN 302052; EN 304484; EN 393507; EN 393510; GLUTAMATE RECEPTOR; HALXAZONE; IDEBENONE; NEUROPROTECTIVE AGENT; NORPHENAZONE; PHENAZOSTATIN A; PHENAZOSTATIN B; PHENAZOSTATIN C; PROTEIN INHIBITOR; S 24429; S 24718; S 32502 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; THIOCTIC ACID; TROLOX C; U 104067F; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; CELL CYCLE; DEGENERATIVE DISEASE; DNA DAMAGE; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN INDUCTION; PROTEIN SECRETION; REVIEW;

ALZHEIMER DISEASE; ANTIOXIDANTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CASPASES; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROMES C; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOCHONDRIA; N-METHYLASPARTATE; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 40849135716     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2008.30.1.1090962     Document Type: Review

References (187)

1. Kerr, J.F.R. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002, 181/182: 471-4.
2. Van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M, Martin, S.J., Vandenabeele, P. The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell Death Differ 2002, 9: 1031-42.
3. Nicotera, P., Leist, M. Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ 1997, 4: 435-42.
4. Lockshin, R.A., Zakari, Z. Apoptosis, autophagy and more. Int J Biochem Cell Biol 2004, 36: 2405-19.
5. Maccioni, R.B., Munoz, J.P., Barbeito, L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001, 32: 367-81.
6. Shimohama, S. Apoptosis in Alzheimer's disease. An update. Apoptosis 2000, 5: 9-16.
7. Willingham, M.C. Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 1999, 47: 1101-9.
8. Troy, C.M., Salvesen, G.S. Caspases on the brain. J Neurosci Res 2002, 69: 145-50.
9. Friedlander, R.M. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003, 348: 1365-75.
10. Gastard, M.C., Troncoso, J.C., Koliatsos, V.E. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003, 54: 393-8.
11. Garcia-Calvo, M., Peterson, E.P., Letting, B., Ruel, R., Nicholson, D.W., Thornberry, N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998, 273: 32608-13.
12. LeBlanc, A., Liu, H., Goodyer, C., Bergeron, C., Hammond, J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem 1999, 274: 23426-36.
13. Haass, C. Apoptosis. Dead end for neurodegeneration? Nature 1999, 399: 204-5.
14. Zhang, Y., Goodyer, C., LeBlanc, A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J Neurosci 2000, 20: 8384-9.
15. Harada, J., Sugimoto, M. Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res 1999, 842: 311-23.
16. Jordan, J., Galindo, M.F., Miller, R.J. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J Neurochem 1997, 68: 1612-21.
17. D'Mello, S.R., Chin, P.C. Treating neurodegenerative conditions through the understanding of neuronal apoptosis. Curr Drug Targets CNS Neurol Disord 2005, 4: 3-23.
18. Stavrovskaya, LG., Kristal, B.S. The powerhouse takes control of the cell: Is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med 2005, 38: 687-97.
19. Hynd, M.R., Scott, H.L., Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004, 45: 583-95.
20. Rostovtseva, T.K., Tan, W., Colombini, M. On the role of VDAC in apoptosis: Fact and fiction. J Bioenerg Biomembr 2005, 37: 129-42.
21. Zhu, X., Smith, M.A., Perry, G., Aliev, G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2004, 19: 345-52.
22. Gastard, M.C., Troncoso, J.C., Koliatsos, V.E. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003, 54: 393-8.
23. Aliev, G., Smith, M.A., de la Torre, J.C., Perry, G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 2004, 4: 649-63.
24. Akgul, C., Moulding, D.A., Edwards, S.W. Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61: 2189-99.
25. Przedborski, S. Programmed cell death in amyotrophic lateral sclerosis: A mechanism of pathogenic and therapeutic importance. Neurologist 2004, 10: 1-7.
26. Liston, P., Fong, W.G., Korneluk, R.G. The inhibitors of apoptosis: There is more to life than Bcl2. Oncogene 2003, 22: 8568-80.
27. Lee, D., Long, S.A., Adams, J.L. et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 2000, 275: 16007-14.
28. Zhu, X., Lee, H.G., Casadesus, G. et al. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005, 31: 205-17.
29. Moreira, P.I., Smith, M.A., Zhu, X., Santos, M.S., Oliveira, C.R., Perry G. Therapeutic potential of oxidant mechanisms in Alzheimer's disease. Expert Rev Neurother 2004, 4: 995-1004.
30. Castellani, RJ., Honda, K., Zhu, X. et al. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 2004, 3: 319-26.
31. Zhu, X., Raina, A.K., Perry, G., Smith, M.A. Alzheimer's dis ease: The two-hit hypothesis. Lancet Neurol 2004, 3: 219-26.
32. Hertweck, M., Baumeister, R. Automated assays to study longevity in C. elegans. Mech Ageing Dev 2005, 126: 139-45.
33. Houthoofd, K., Braeckman, B.P., Johnson, T.E., Vanfleteren, J.R. Extending life-span in C. elegans. Science 2004, 305: 1238-9.
34. Hughes, K.A., Reynolds, R.M. Evolutionary and mechanistic theories of aging. Annu Rev Entomol 2005, 50: 421-45.
35. Droge, W. Oxidative stress and aging. Adv Exp Med Biol 2003, 543: 191-200.
36. Ishii, N., Senoo-Matsuda, N., Miyake, K. et al. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004, 125: 41-6.
37. de Haan, J.B., Susil, B., Pritchard, M., Kola, I. An altered antioxidant balance occurs in Down's syndrome fetal organs: Implications for the "gene dosage effect" hypothesis. J Neural Transm Suppl 2003, 67: 67-83.
38. Stefanis, L. Caspase-dependent and -independent neuronal death: Two distinct pathways to neuronal injury. Neuroscientist 2005, 11: 50-62.
39. Nguyen, H.N., Wang, C., Perry, D.C. Depletion of intracellular calcium stores is toxic to SH-SY5Y neuronal cells. Brain Res 2002, 924: 159-66.
40. Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C., LeBlanc, A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004, 165: 523-31.
41. Nakashima, H., Ishihara, T., Yolota, O., Terada, S., Trojanowski, J.Q., Lee, V.M., Kuroda, S. Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med 2004, 37: 176-86.
42. Behl, C. Apoptosis and Alzheimer's disease. J Neural Trans 2000, 107: 1325-44.
43. Feng, Z., Zhang, J.T. Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004, 37: 1790-801.
44. Feng, Z., Zhang, J.T. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. J Pineal Res 2004, 37: 257-66.
45. Harnett, J.J., Auguet, M., Viossat, I., Dolo, C., Bigg, D., Chabrier, P.E., I. Novel lipoic acid analogues that inhibit nitric oxide synthase. Bioorg Med Chem Lett 2002, 12: 1439-42.
46. Langlois, A.BN82451: A neuroprotective drug acting at mitochondrial level. In: The 33rd Annual Meeting of the Society for Neuroscience, Nov. 8-12, 2003, New Orleans. Abstract no. 528.3.
47. Kotoda, N., Shin-ya, K., Furihata, K., Hayakawa, Y., Seto, H. Isolation and structure elucidation of novel neuronal cell protecting substances, carbazomadurins A and B produced by Actinomadura madurae. J Antibiot 1997, 50: 770-2.
48. Katoh, H., Katoh, H., Shin-Ya, K., Furihata, K., Furihata, K., Hayakawa, Y.L. A novel neuronal cell protecting substance, halxazone, produced by Streptomyces halstedii. J Antibiot 2002, 55: 508-10.
49. Dorey, G., Lockhart, B., Lestage, P., Casara, P. New quinolinic derivatives as centrally active antioxidants. Bioorg Med Chem Lett 2000, 10: 935-40.
50. Kim, W.G., Ryoo, I.J., Yun, B.S., Shin-Ya, K., Seto, H., Yoo, I.D. New diphenazines with neuronal cell protecting activity, phenazostatins A and B, produced by Streptomyces sp. J Antibiot 1997, 50:715-21.
51. Kim, W.G., Ryoo, I.J., Yun, B.S., Shin-Ya, K., Seto, H., Yoo, I.D. Phenazostatin C, a new diphenazine with neuronal cell protecting activity from Streptomyces sp. J Antibiot 1999, 52: 758-61.
52. Demerle-Pallardy, C., Roubert, V., Marin, J.G., Auguet, M., Chabrier, P.E. Neuroprotection by BN 80933 against oxidative stress on a mouse hippocampal cell line and hypoxia on primary cortical neuronal cultures. Abstr Soc Neurosci 1999, 25 (Part 2): Abstract no. 837.12.
53. Largeron, M., Lockhart, B., Pfeiffer, B., Fleury, M.B. Synthesis and in vitro evaluation of new-8-amino-1 ,4-benzoxazine derivatives as neuroprotective antioxidants. J Med Chem 1999, 42: 5043-55.
54. Lockhart, B., Favale, D., Cuisinier, C. et al. Protective action of tert-butyl-phenylnitrone (t-BPN) and S-32502-1 in vitro and in vivo models of oxidative stress. Fundam Clin Pharmacol 1999, 13 (Suppl 1): Abstract no. PW31.
55. L-carnitine protects against amyloid-beta neurotoxicity: Roles of oxidative buffering and ATP levels. Neurochem Res 2002, 27: 551-5.
56. Eberhardt, O., Schulz, J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 2003, 139: 135-51.
57. Miklya, I., Knoll, B., Knoll, J. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life Sci 2003, 72: 2641-8.
58. Etminan, M., Gill, S.S., Samii, A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: A metaanalysis. Lancet Neurol 2005, 4: 362-5.
59. Olanow, C.W., Jankovic, J. Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005, 20 (Suppl 11): S3-10.
60. Fariss, M.W., Zhang, J.G. Vitamin E therapy in Parkinson's disease. Toxicology 2003, 189: 129-46.
61. Grunblatt, E., Mandel, S., Jacob-Hirsch, J. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004, 111: 1543-73.
62. Grunblatt, E. The benefits of microarrays as tools for studying neuropsychiatric disorders. Drugs Today (Barc) 2004, 40: 147-56.
63. Ternansky, R.J., Linton, S.D., Karanesky, D.S. Structure-activity relationship of a series of oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. In: The 221st ACS National Meet, Apr 1-5, 2001, San Diego. Absract no. MEDI 75.
64. Ullman, B.R., Karanewsky, D.S., Aja, T. Warhead structure-activity relationships within a series of (1-naphthyloxy)acetyl-Val-Asp hetero methyl ketones. In: The 221st ACS National Meet, Apr 1-5, 2001, San Diego. Abstract no. MEDI 78.
65. Lavrik, I.N., Golks, A., Krammer, P.H. Caspases: Pharmacological manipulation of cell death. J Clin Invest 2005, 115: 2665-72.
66. Legos, J.J., Lee, D., Erhardt, J.A. Caspase inhibitors as neuroprotective agents. Expert Opin Emerg Drugs 2001, 6: 81-94.
67. Broker, L.E., Kruyt, F.A., Giaccone, G. Cell death independent of caspases: A review. Clin Cancer Res 2005, 11: 3155-62.
68. Han, B.S., Hong, H.S., Choi, W.S., Markelonis, G.J., Oh, T.H., Oh, Y.J. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 2003, 23: 5069-78.
69. Dodel, R.C., Du, Y., Bales, K.R., Ling, Z.D., Carvey, P.M., Paul, S.M. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4- phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience 1998, 86: 701-7.
70. Du, Y., Dodel, R.C., Bales, K.R., Jemmerson, R., Hamilton-Byrd, E., Paul, S.M. Involvement of a caspase-3-like cysteine protease in 1-methyl-4-phenylpyridinium-mediated apoptosis of cultured cerebellar granule neurons. J Neurochem 1997, 69: 1382-8.
71. Pompl, P.N., Yemul, S., Xiang, Z. et al. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer's disease. Arch Neurol 2003, 60: 369-76.
72. Rohn, T.T., Rissman, R.A., Davis, M.C., Kim, Y.E., Cotman, C.W., Head, E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 2002, 11: 341-54.
73. Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C., LeBlanc, A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004, 165: 523-31.
74. Gastard, M.C., Troncoso, J.C., Koliatsos, V.E. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003, 54: 393-8.
75. Ayala-Grosso, C., Ng, G., Roy, S., Robertson, G.S. Caspase-cleaved amyloid precursor protein in Alzheimer's disease. Brain Pathol 2002, 12:430-41.
76. Han, B.S., Hong, H.S., Choi, W.S., Markelonis, G.J., Oh, T.H., Oh, Y.J. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 2003, 23: 5069-78.
77. Bilsland, J., Roy, S., Xanthoudakis, S. et al. Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci 2002, 22: 2637-49.
78. Ona, V.O., Li, M., Vonsattel, J.P. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399: 263-7.
79. Bizat, N., Hermel, J.M., Humbert, S. et al. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: Implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 2003, 278: 43245-53.
80. Pang, Z., Bondada, V., Sengoku, T., Siman, R., Geddes, J.W. Calpain facilitates the neuron death induced by 3-nitropropionic acid and contributes to the necrotic morphology. J Neuropathol Exp Neurol 2003, 62: 633-43.
81. Nasr, P., Gursahani, H.I., Pang, Z. et al. Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membranepotential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochem Int 2003, 43: 89-99.
82. Fink, K., Zhu, J., Namura, S. et al. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab 1998, 18: 1071-6.
83. Schielke, G.P., Yang, G.Y., Shivers, B.D., Betz, A.L. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 1998, 18: 180-5.
84. Knoblach, S.M., Alroy, D.A., Nikolaeva, M., Cernak, I., Stoica, B.A., Faden, A.I. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 2004, 24: 1119-32.
85. Koh, D.W., Dawson, T.M., Dawson, V.L. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 2005, 52: 5-14.
86. Wang, H., Yu, S.W., Koh, D.W. et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci 2004, 24: 10963-73.
87. Cregan, S.P., Dawson, V.L., Slack, R.S. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004, 23: 2785-96.
88. Cregan, S.P., Fortin, A., MacLaurin, J.G. et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002, 158: 507-17.
89. Yu, S.W., Wang, H., Poitras, M.F. et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297: 259-63.
90. L-lysine chloromethyl ketone (TLCK) suppresses neuritis degeneration caused by different experimental paradigms including in vitro Wallerian degeneration. Brain Res 2004, 1030: 81-93.
91. Mitsui, C., Sakai, K., Ninomiya, T., Koike, T. Involvement of TLCK-sensitive serine protease in colchicine-induced cell death of sympathetic neurons in culture. J Neurosci Res 2001, 6: 601-11.
92. Rideout, H.J., Zang, E., Yeasmin, M. et al. Inhibitors of trypsin-like serine proteases prevent DNA damage-induced neuronal death by acting upstream of the mitochondrial checkpoint and of p53 induction. Neuroscience 2001, 107: 339-52.
93. Movsesyan, V.A., Yakovlev, A.G., Fan, L., Faden, A.I. Effect of serine protease inhibitors on posttraumatic brain injury and neuronal apoptosis. Exp Neurol 2001, 167: 366-75.
94. Hook, V., Toneff, T., Bogyo, M. et al. Inhibition of cathepsin B reduces beta-amyloid production in regulatedsecretory vesicles of neuronal chromaffin cells: Evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol Chem 2005, 386: 931-40.
95. Nakanishi, H., Yamamoto, K. Cathepsin E in the central nervous system. Adv Exp Med Biol 1998, 436: 213-7.
96. Nakanishi, H., Amano, T., Sastradipura, D.F. et al. Increased expression of cathepsins E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein. J Neurochem 1997, 68: 739-49.
97. Nakanishi, H., Tsukuba, T., Kondou, T., Tanaka, T., Yamamoto, K. Transient forebrain ischemia induces increased expression and specific localization of cathepsins E and D in rat hippocampus and neostriatum. Exp Neurol 1993, 121: 215-23.
98. Lang-Rollin, I.C.J., Ridout, H.J., Stefanis, L. Mechanisms of caspase-independent neuronal death: Energy depletion and free radical generation. J Neurosci 2003, 35: 11015-25.
99. Yamamoto, A., Tomoo, K., Matsugi, K. et al. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: Crystal structure of cathepsin B-E64c complex. Biochim Biophys Acta 2002, 1597: 244-51.
100. Kuwako, K., Nishimura, I., Uetsuki, T., Saido, T.C., Yoshikawa, K. Activation of calpain in cultured neurons overexpressing Alzheimer amyloid precursor protein. Brain Res Mol Brain Res 2002, 107: 166-75.
101. Lee, M.S., Kwon, Y.T., Li, M., Peng, J., Friedlander, R.M., Tsai, L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000 405: 360-4.
102. Samara, C., Tavernarakis, N. Calcium-dependent and aspartyl proteases in neurodegeneration and ageing in C. elegans. Ageing Res Rev 2003, 2: 451-71.
103. Rami, A. Ischemic neuronal death in the rat hippocampus: The calpain-calpastatin-caspase hypothesis. Neurobiol Dis 2003, 13: 75-88.
104. Ray, S.K., Hogan, E.L., Banik, N.L. Calpain in the pathophysiology of spinal cord injury: Neuroprotection with calpain inhibitors. Brain Res Brain Res Rev 2003, 42: 169-85.
105. Ray, S.K., Banik, N.L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: Therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr Drug Targets CNS Neurol Disord 2003, 2: 173-89.
106. Cheung, Z.H., Ip, N.Y. Cdk5: Mediator of neuronal death and survival. Neurosci Lett 2004, 361: 47-51.
107. Tsai, L.H., Lee, M.S., Cruz, J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004, 1697: 137-42.
108. Lim, A.C., Qi, R.Z. Cyclin-dependent kinases in neural development and degeneration. J Alzheimers Dis 2003, 5: 329-35.
109. Lee, M.S., Tsai, L.H. Cdk5: One of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 2003, 5: 127-37.
110. Weishaupt, J.H., Neusch, C., Bahr, M. Cyclin-dependent kinase 5 (CDK5) and neuronal cell death. Cell Tissue Res 2003, 312: 1-8.
111. Alvarez, A., Toro, R., Caceres, A., Maccioni, R.B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 1999, 459: 421-6.
112. Alvarez, A., Munoz, J.P., Maccioni, R.B. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 2001, 264: 266-74.
113. Munoz, J.P., Alvarez, A., Maccioni, R.B. Increase in the expression of the neuronal cyclin-dependent protein kinase cdk-5 during differentiation of N2A neuroblastoma cells. Neuroreport 2000, 11: 2733-8.
114. Nakamura, S., Kawamoto, Y., Nakano, S., Akiguchi, I., Kimura, J. p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 1997, 94: 153-7.
115. Nguyen, M.D., Julián, J.P. Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neurosignals 2003, 12: 215-20.
116. Nguyen, M.D., Mushynski, W.E., Julien, J.P. Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 2002, 9: 1294-306.
117. Battaglia, F., Trinchese, F., Liu, S., Walter, S., Nixon, R.A., Arancio, O. Calpain inhibitors, a treatment for Alzheimer's disease: Position paper. J Mol Neurosci 2003, 20: 357-62.
118. Liu, T., Perry, G., Chan, H.W. et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004, 88: 554-63.
119. Wang, K.K., Posmantur, R., Nath, R. et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 1998, 273: 22490-7.
120. Bizat, N., Hermel, J.M., Humbert, S. et al. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: Implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 2003, 278: 43245-53.
121. Waterhouse, N.J., Finucane, D.M., Green, D.R. et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ 1998, 5: 1051-61.
122. Van de Craen, M., Van den Brande, I., Declercq, W. et al. Cleav age of caspase family members by granzyme B: A comparative study in vitro. Eur J Immunol 1997, 27: 1296-9.
123. Vancompernolle, K., Van Herreweghe, F., Pynaert, G. et al. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett 1998, 438: 150-8.
124. Kitao, Y., Ozawa, K., Miyazaki, M. et al. Expression of the endoplasmic reticulum molecular chaperone (ORP150) rescues hippocampal neurons from glutamate toxicity. J Clin Invest 2001, 108: 1439-50.
125. Chin, P.C., Majdzadeh, N., D'Mello, S.R. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005, 137: 193-201.
126. Umemura, E., Sasaki, K., Setsu, F.FX0685, a new triazole antifungal agent: Synthesis and structure-activity relationships of novel triazole containing an imidazo[2,1-b]thiazole carboxamide moiety. In: The 5th AFMC International Medicinal Chemistry Symposium, Oct 14-17, 2003, Kyoto. Abstract no. B-2.
127. Engler, T.A., Malhotra, S., Burkholder, T.P. et al. The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg Med Chem Lett 2005, 15: 899-903.
128. Engler, T.A., Henry, J.R., Malhotra, S. et al. Substituted 3-imidazo[1 ,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl) pyrrole-2,4-diones as highly selective and potent Inhibitors of glycogen synthase kinase-3. J Med Chem 2004, 47: 3934-7.
129. Mora, A., Sabio, G., Gonzalez-Polo, R.A. et al. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem 2001, 78: 199-206.
130. Bhat, R.V., Budd, R., Haeberlein, S.L., Avila, J. Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 2004, 89: 1313-7.
131. Enguita, M., DeGregorio-Rocasolano, N., Abad, A., Trullas, R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol 2005, 67: 1237-46.
132. Facci, L., Stevens, D.A., Skaper, S.D. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 2003, 14: 1467-70.
133. Cross, D.A., Culbert, A.A., Chalmers, K.A., Facci, L., Skaper, S.D., Reith, A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001, 77: 94-102.
134. Cohen, P., Goedert, M. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004, 3: 479-87.
135. Jope, R.S., Johnson, G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29: 95-102.
136. Kaytor, M.D., Orr, H.T. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002, 12: 275-8.
137. Hoozemans, J.J., O'Banion, M.K. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005, 4: 307-15.
138. Patrignani, P., Tacconelli, S., Sciulli, M.G., Capone, M.L. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005, 48: 352-9.
139. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63: 901-10.
140. O'Banion, M.K. COX-2 and Alzheimer's disease: Potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999, 8: 1521-36.
141. Mayer, M.L. Glutamate receptor ion channels. Curr Opin Neurobiol 2005, 15: 282-8.
142. Palmer, C.L., Cotton, L., Henley, J.M. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 2005, 57: 253-77.
143. Wang, C.X., Shuaib, A. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 2005, 4: 143-51.
144. Arundine, M., Tymianski, M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004, 61: 657-68.
145. Danysz, W., Parsons, C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int J Geriatr Psychiatry 2003, 18 (Suppl 1): S23-32.
146. Arundine, M., Tymianski, M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 4: 325-37.
147. Mandel, S., Grunblatt, E., Riederer, P., Gerlach, M., Levites, Y., Youdim, M.B. Neuroprotective strategies in Parkinson's disease: An update on progress. CNS Drugs 2003, 17: 729-62.
148. Jarrott, B., Callaway, J.K., Jackson, W.R., Beart, P.M. Development of a novel arylalkylpiperazine compound (AM-36) as a hybrid neuroprotective drug. Drug Dev Res 1999, 46: 261-70.
149. Parsons, C.G., Danysz, W., Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999, 38: 735-67.
150. Chen, H.S., Lipton, S.A. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Exp Ther 2005, 314: 961-71.
151. Danysz, W., Parsons, C.G. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res 2002, 4: 119-26.
152. Olney, J.W., Wozniak, D.F., Farber, N.B. Glumate receptor dysfunction and Alzheimer's disease. Restor Neurol Neurosci 1998, 13: 75-83.
153. Michaelis, M.L. Drugs targeting Alzheimer's disease: Some things old and some things new. J Pharmacol Exp Ther 2003, 304: 897-904.
154. Lee, H.G., Zhu, X., Ghanbari, H.A. et al. Differential regulation of glutamate receptors in Alzheimer's disease. Neurosignals 2002, 11: 282-92.
155. Wilcock, G.K. Memantine for the treatment of dementia. Lancet Neurol 2003, 2: 503-5.
156. Molinuelo, J.L., Llado, A., Rami, L. Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimers Dis Other Demen 2005, 20: 77-85.
157. Plosker, G.L., Lyseng-Williamson, K.A. Memantine: A pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005, 23: 193-206.
158. Beal, M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 2000, 23: 298-304.
159. Schulz, J.B., Matthews, R.T., Henshaw, D.R., Beal, M.F. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience 1996, 71: 1043-8.
160. Beal, M.F., Ferrante, R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004, 5: 373-84.
161. Malcon, C., Kaddurah-Daouk, R., Beal, M.F. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res 2000, 860: 195-8.
162. Lancelot, E., Beal, M.F. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998, 116: 331-47.
163. Giovanni, A., Wirtz-Brugger, F., Keramaris, E., Slack, R., Park, D.S. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem 1999, 274: 19011-6.
164. Copani, A., Sortino, M.A., Caricasole, A. et al. Erratic expression of DNA polymerases by beta-amyloid causes neuronal death. FASEB J 2002, 16: 2006-8.
165. Copani, A., Melchiorri, D., Caricasole, A. et al. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. J Neurosci 2002, 22: 3963-8.
166. Copani, A., Condorelli, F., Canonico, P.L., Nicoletti, F., Sortino, M.A. Cell cycle progression towards Alzheimer's disease. Funct Neurol 2001, 16: 11-5.
167. Copani, A., Uberti, D., Sortino, M.A., Bruno, V., Nicoletti, F., Memo, M. Activation of cell-cycle-associated proteins in neuronal death: A mandatory or dispensable path? Trends Neurosci 2001 24: 25-31.
168. Hou, S.T., Callaghan, D., Fournier, M.C. et al. The transcription factor E2F1 modulates apoptosis of neurons. J Neurochem 2000, 75: 91-100.
169. Hou, S.T., Cowan, E., Walker, T., Ohan, N., Dove, M., Rasqinha, I., MacManus, J.P. The transcription factor E2F1 promotes dopamine-evoked neuronal apoptosis by a mechanism independent of transcriptional activation. J Neurochem 2001, 78: 287-97.
170. Jordan-Sciutto, K.L., Wang, G., Murphy-Corb, M., Willey, C.A. Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. Am J Pathol 2000, 157: 497-507.
171. Jordan-Sciutto, K.L., Dorsey, R., Chalovich, E.M., Hammond, R.R., Achim, C.L. Expression patterns of retinoblastoma protein in Parkinson's disease. J Neuropathol Exp Neurol 2002, 61: 358-67.
172. Yang, Y., Geldmacher, D.S., Herrup, K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 2001, 21: 2661-8.
173. Yang, Y., Mufson, E.J., Herrup, K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003, 23: 2557-63.
174. Jordan-Sciutto, K.L., Dorsey, R., Chalovich, E.M., Hammond, R.R., Achim, C.L. Expression patterns of retinoblastoma protein in Parkinson's disease. J Neuropathol Exp Neurol 2003, 62: 68-74.
175. Vincent, A.M., Backus, C., Taubman, A.A., Feldman, E.L. Identification of candidate drugs for the treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6: 29-36.
176. Stefanis, L., Park, D.S., Friedman, W.J., Greene, L.A. Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 1999, 19: 6235-47.
177. Padmanabhan, J., Park, D.S., Greene, L.A., Shelanski, M.L. Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J Neurosci 1999, 19: 8747-56.
178. O'Hare, M.J., Hou, S.T., Morris, E.J. et al. Induction and modulation of cerebellar granule neuron death by E2F-1. J Biol Chem 2000, 18, 275: 25358-64.
179. Park, D.S., Obeidat, A., Giovanni, A., Greene, L.A. Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol. Aging 2000, 21: 771-81.
180. Kasten, M., Giordano, A. pRb and the CDKs in apoptosis and the cell cycle. Cell Death Differ 1998, 5: 132-40.
181. Kruman, I.I., Wersto, R.P., Cardozo-Pelaez, F. et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004, 41: 549-61.
182. Trinh, E., Boutillier, A.L., Loeffler, J.P. Regulation of the retinoblastoma-dependent Mdm2 and E2F-1 signaling pathways during neuronal apoptosis. Mol Cell Neurosci 2001, 17: 342-53.
183. Xiang, H., Hochman, D.W., Saya, H., Fujiwara, T., Schwartzkroin, P.A., Morrison, R.S. Evidence for p53-mediated modulation of neuronal viability. J Neurosci 1996, 16: 6753-65.
184. Villunger, A., MIchalak, E.M., Copultas, L. et al. P53 and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003, 302: 1036-8.
185. Culmsee, C., Mattson, M.P. p53 in neuronal apoptosis. Biochem Biophys Res Commun 2005, 331: 761-77.
186. Duan, W., Zhu, X., Ladenheim, B. et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002, 52: 597-606.
187. Culmsee, C., Zhu, X., Yu, Q.S. et al. A synthetic inhibitor of p53